Targeting HER2: A report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials

類似資料

• In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
  著者:: Wong, Karen J, 等
  出版事項: (2011)
• Preparation, biological evaluation and pharmacokinetics of human anti-HER1 monoclonal antibody, Panitumumab, labeled with (86)Y for quantitative PET imaging of carcinoma
  著者:: Nayak, Tapan K., 等
  出版事項: (2010)
• PET imaging of HER1-expressing xenografts in mice with (86)Y-CHX-A”-DTPA-cetuximab
  著者:: Nayak, Tapan K., 等
  出版事項: (2010)
• HER1-Targeted (86)Y-Panitumumab Possesses Superior Targeting Characteristics than (86)Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts
  著者:: Nayak, Tapan K., 等
  出版事項: (2011)
• Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial
  著者:: Milenic, Diane E., 等
  出版事項: (2015)